Inactive Instrument

Kadmon Holdings, Inc.

Equities

KDMN

US48283N1063

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma RE
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Global BMI Index CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P TMI Index CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Biotechnology Select Industry Index CI
Sanofi Closes on Kadmon Acquisition MT
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Composite Index CI
Sanofi completed the acquisition of Kadmon Holdings, Inc.. CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Biotechnology Index CI
Kadmon Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Earnings Flash (KDMN) KADMON HOLDINGS Reports Q3 Revenue $14.7M MT
Kadmon : Health Care Stocks Edging Higher At Close MT
Sector Update: Health Care MT
Kadmon : Announces Expiration of HSR Waiting Period in Sanofi Deal MT
North American Morning Briefing : Stock Futures -3- DJ
KADMON : Mizuho Securities Downgrades Kadmon Holdings to Neutral from Buy, Adjusts Price Target to $9.50 from $13 MT
KADMON : UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9 MT
North American Morning Briefing : Stock Futures -3- DJ
KADMON : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger MT
KADMON : Jefferies Downgrades Kadmon Holdings to Hold from Buy, Adjusts Price Target to $9.50 from $10 MT
ADRs End Lower; Nio, Sanofi Among Companies Actively Trading DJ
Health Care Flat On Defensive Bias -- Health Care Roundup DJ
Alector : Health Care Stocks Edging Lower Just Ahead of Wednesday Close MT
Flora Growth : Health Care Stocks Fighting to Overcome Market Downdrafts MT
Top Midday Gainers MT
Stoxx Europe 600 : European Stocks Close Lower Amid Economic Growth Concerns, Rising COVID-19 Cases MT
Chart Kadmon Holdings, Inc.
More charts
Kadmon Holdings, Inc. is a biopharmaceutical company, which is engaged in discovering, developing, and delivering therapies for unmet medical needs. The Company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. It is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The Company has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
More about the company
  1. Stock
  2. Equities
  3. Stock Kadmon Holdings, Inc. - Nyse
  4. News Kadmon Holdings, Inc.
  5. Kadmon : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger